The Discovery of BPC-157

Overview

BPC-157, short for "Body Protection Compound 157," is a 15-amino-acid peptide sequence derived from a larger gastric juice protein originally isolated by a Croatian research team led by Predrag Sikirić at the University of Zagreb. The parent protein, which the group called BPC, was identified in human and animal gastric juice in the late 1980s and early 1990s and appeared to have wide-ranging protective effects in the gastrointestinal tract and beyond.

From the parent molecule, the researchers synthesized a stable 15-amino-acid fragment that retained and in some models exceeded the biological activity of the full-length protein. This fragment became known as BPC-157 and has been the subject of hundreds of preclinical papers examining effects on gastric ulcers, tendon and ligament healing, bone repair, vascular remodeling, and inflammatory bowel disease in animal models.

BPC-157 is not approved as a human drug by any major regulatory agency. It is studied as an experimental compound and is on the WADA Prohibited List as of 2022. Most published human safety and efficacy data are limited, and clinical translation has been slow compared with the breadth of animal work.

Key People

• Predrag Sikirić: Croatian gastroenterologist and pharmacologist at the University of Zagreb who led the original BPC research program.
• Sven Seiwerth: Croatian pathologist and long-time collaborator on BPC-157 studies.
• Rudolf Rucman: Chemist involved in early peptide characterization.
• The broader Zagreb group has published extensively on BPC-157 across physiology, pharmacology, and clinical sub-disciplines.

Timeline

• Late 1980s: The Sikirić group begins isolating protective fractions of gastric juice in rodent ulcer models.
• Early 1990s: The 15-amino-acid sequence is identified and named BPC-157.
• 1993–2000: Initial preclinical publications describe wound healing, anti-ulcer, and vascular effects.
• 2000s: Expanded studies into tendon, ligament, nerve, and brain repair.
• 2010s: Growing non-clinical interest from the research community; no approved indications.
• 2022: BPC-157 is added to the WADA Prohibited List as a non-specified substance.

Background

BPC-157 emerged from a classic "activity-guided fractionation" program. Sikirić's laboratory was interested in endogenous factors that protect the gastric mucosa against stress, alcohol, and nonsteroidal anti-inflammatory drugs. Gastric juice fractions that blocked ulcer formation were progressively purified, sequenced, and narrowed down to the 15-residue peptide. The synthetic version proved unusually stable in the acidic gastric environment and resistant to proteolysis, making it a practical experimental tool.

Subsequent animal studies reported effects on nitric oxide pathways, angiogenesis, growth hormone receptor expression in tendon, and the dopaminergic system. Despite extensive preclinical data, the precise receptor or receptors mediating BPC-157's effects remain uncertain, and several proposed mechanisms are still debated.

Modern Relevance

BPC-157 has become one of the most widely discussed "research peptides" outside of mainstream pharmaceutical development. It is frequently mentioned in connection with athletic recovery, joint injuries, and inflammatory conditions, but regulated clinical data remain limited. Because the peptide is not approved for human use, medical-grade manufacturing, quality control, and formal safety data are not standardized.

Researchers studying BPC-157 today often focus on mechanism — how a short, relatively simple peptide might exert such varied effects across tissues — and on the translation gap between rodent work and controlled human trials. The story of BPC-157 also illustrates how preclinical enthusiasm can outrun rigorous clinical validation, a pattern common to many experimental peptides. See also understanding-peptide-research for a broader methodological discussion.

Related Compounds

• BPC-157
• Thymosin Beta-4
• TB-500
• Pentadecapeptide
• Growth Hormone Releasing Peptides